A Clinical Study to Assess the Safety and Effectiveness of Scalp Cream for Symptom Relief and Microbiome Balance in Mild-moderate Seborrheic Dermatitis Patients.

NCT ID: NCT07063615

Last Updated: 2025-07-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

34 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-07-12

Study Completion Date

2025-10-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the safety and efficacy of scalp cream for Symptom Relief and Microbiome Balance in mild-moderate Seborrheic Dermatitis patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A total of 34 participants, including males and non-pregnant, non-lactating females aged between 20 and 55 years (inclusive) with a confirmed diagnosis of mild to moderate seborrheic dermatitis, will be enrolled in the study. Enrolment will be based on scalp skin type, which may be classified as dry, oily, or combination. Participants will be randomized in a 22:12 ratio to receive either Treatment A or Treatment B, respectively.

The study aims to complete evaluations for 30 participants-20 in the Treatment A group and 10 in the Treatment B group. The potential patient will be screened as per the inclusion and exclusion criteria only after obtaining the written informed consent from the patients. Subjects will be pre-screened by the screening department of NovoBliss Research. Subjects will be called on the telephone by the recruiting department prior the enrolment visit. Patients will be told during screening (prior to enrolment) not to use any hair product including hair oil and hair cream on the study visit day.

There will be total of 4 visits during the study. The duration of the study will be 60 (+2 days) from the enrolment. Subjects will be instructed to visit the facility as per below visits.

Visit 01(Within 15 Days): Screening, ICD obtained. Visit 02 (Day 1): Enrolment, Baseline Evaluations, Treatment Usage, Post Treatment Usage Evaluations at 30 mins (T30 Mins).

Visit 03 (Day 30 +2 Days): Post-usage evaluation Visit 04 (Day 60 +2 Days): Post-usage evaluation and End of Study Telephonic Follow Up (Day 90 + 2 Days): A scripted telephonic follow-up schedule, will be implemented for Treatment group A to assess whether any seborrheic dermatitis (SD) symptoms have recurred following discontinuation of the treatment, 30 days after study completion.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Seborrheic Dermatitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators
Double Blind Study

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Microbiome-Powered Cream

Mode of Usage: Apply a generous amount of the cream to the affected area of the scalp. Gently part the hair using a wide-tooth comb or your fingertips to ensure direct contact with the scalp. Extend slightly beyond affected areas.

Massage the cream gently into the skin until fully absorbed. Do not rinse off after application.

Frequency: Apply twice daily - once after the morning shower and once before bedtime.

Route of Administration: Topical Note For best results, the cream should be applied within 5 minutes of towel drying, while the scalp is slightly damp and soft. At night, ensure the cream is fully absorbed before lying down to avoid transfer to bedding materials like pillows or sheets.

Group Type EXPERIMENTAL

Microbiome-Powered Cream

Intervention Type OTHER

Mode of Usage: Apply a generous amount of the cream to the affected area of the scalp. Gently part the hair using a wide-tooth comb or your fingertips to ensure direct contact with the scalp. Extend slightly beyond affected areas.

Massage the cream gently into the skin until fully absorbed. Do not rinse off after application.

Frequency: Apply twice daily - once after the morning shower and once before bedtime.

Route of Administration: Topical Note Ensure the scalp is completely dry (within 5 minutes of towel-drying post-shower) before applying the cream. At night, ensure the cream is fully absorbed before lying down to avoid transfer to bedding materials like pillows or sheets.

Placebo Hair Cream

Mode of Usage: Apply a generous amount of the cream to the affected area of the scalp. Gently part the hair using a wide-tooth comb or your fingertips to ensure direct contact with the scalp. Extend slightly beyond affected areas.

Massage the cream gently into the skin until fully absorbed. Do not rinse off after application.

Frequency: Apply twice daily - once after the morning shower and once before bedtime.

Route of Administration: Topical Note For best results, the cream should be applied within 5 minutes of towel drying, while the scalp is slightly damp and soft. At night, ensure the cream is fully absorbed before lying down to avoid transfer to bedding materials like pillows or sheets.

Group Type PLACEBO_COMPARATOR

Placebo Hair Cream

Intervention Type OTHER

Mode of Usage: : Apply a generous amount of the cream to the affected area of the scalp. Gently part the hair using a wide-tooth comb or your fingertips to ensure direct contact with the scalp. Extend slightly beyond affected areas.

Massage the cream gently into the skin until fully absorbed. Do not rinse off after application.

Frequency: Apply twice daily - once after the morning shower and once before bedtime.

Route of Administration: Topical Note Ensure the scalp is completely dry (within 5 minutes of towel-drying post-shower) before applying the cream. At night, ensure the cream is fully absorbed before lying down to avoid transfer to bedding materials like pillows or sheets.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Microbiome-Powered Cream

Mode of Usage: Apply a generous amount of the cream to the affected area of the scalp. Gently part the hair using a wide-tooth comb or your fingertips to ensure direct contact with the scalp. Extend slightly beyond affected areas.

Massage the cream gently into the skin until fully absorbed. Do not rinse off after application.

Frequency: Apply twice daily - once after the morning shower and once before bedtime.

Route of Administration: Topical Note Ensure the scalp is completely dry (within 5 minutes of towel-drying post-shower) before applying the cream. At night, ensure the cream is fully absorbed before lying down to avoid transfer to bedding materials like pillows or sheets.

Intervention Type OTHER

Placebo Hair Cream

Mode of Usage: : Apply a generous amount of the cream to the affected area of the scalp. Gently part the hair using a wide-tooth comb or your fingertips to ensure direct contact with the scalp. Extend slightly beyond affected areas.

Massage the cream gently into the skin until fully absorbed. Do not rinse off after application.

Frequency: Apply twice daily - once after the morning shower and once before bedtime.

Route of Administration: Topical Note Ensure the scalp is completely dry (within 5 minutes of towel-drying post-shower) before applying the cream. At night, ensure the cream is fully absorbed before lying down to avoid transfer to bedding materials like pillows or sheets.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\) Age: 20-55 years (both inclusive) at the time of consent. 2) Sex: Males and non-pregnant/non-lactating females (preferably equal number of males and females).

3\) Females of childbearing potential must have a self-reported negative urine pregnancy.

4\) Subject is in good general health as determined by the Investigator on the basis of medical history.

5\) Patients must have a confirmed diagnosis of mild to moderate scalp seborrheic dermatitis, with an ASFS score of at least 16 at the time of screening. The severity grade will be evaluated by the dermatologist using the ASFS scale during the clinical study.

6\) Subject is able to remain on stable doses of contraceptive or replacement hormonal therapy, including no therapy, 6 weeks prior to and for the duration of the study.

7\) If the subject is of childbearing potential, is practicing and agrees to maintain an established method of birth control (IUD, hormonal implant device/injection, regular use of birth control pills or patch, diaphragm, condoms with spermicide or sponge with spermicidal jelly, cream or foam, partner vasectomy or abstinence). Females will be considered as non-childbearing potential if they are surgically sterile, have been post-menopausal for at least 1 year or have had a tubal ligation.

8\) Patients are willing to give written informed consent and are willing to follow the study procedure.

9\) Patients who commit not to use any other medicated/ prescription shampoos/hair care products, any other hair growth products or hair colour or dye, other than the test treatment for the entire duration of the study.

10\) Patients who are having refrigerator at their home for storage of test treatment.

11\) Subject is willing and able to comply with study procedures, including all scheduled visits, treatment applications, and assessments.

12\) Subject is willing and able to follow the study directions, to participate in the study, returning for all specified visits.

13\) Subject must be able to understand and provide written informed consent to participate in the study.

Exclusion Criteria

* 1\) Subject with known allergy or sensitization to test treatment ingredients. 2) Subjects with a history of dermatological scalp conditions other than seborrheic dermatitis or dandruff (e.g., psoriasis, tinea capitis, lichen planopilaris) .

3\) Subject who had taken topical treatment of dandruff for at least 4 weeks. 4) Subject who had taken any systemic treatment for at least 3 months. 5) Subject who have plans of shaving scalp hair during the study. 6) Use of systemic or topical medications (e.g., corticosteroids, immunosuppressants, retinoids) known to affect skin or scalp within the past 3 months, or any medical history likely to interfere with study.

7\) Subject has any concurrent skin disease. 8) History of alcohol or drug addiction. 9) Subjects with an allergy to dairy products. 10) Subjects with a history or current presentation of visibly inflamed, infected, or severely irritated scalp, or known sensitivity to topical or cosmetic products.

11\) Pregnant or breast feeding or planning to become pregnant during the study period.

12\) Use of antibiotics, antifungal medications, or oral/topical probiotics within the past 4 weeks 13) History of chronic illness which may influence the cutaneous state. 14) Subject have participated any clinical research study related to hair care products within past 3 months.
Minimum Eligible Age

20 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Blossom Microbiotics LLC

OTHER

Sponsor Role collaborator

NovoBliss Research Pvt Ltd

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nayan Patel

Role: PRINCIPAL_INVESTIGATOR

NovoBliss Research Private Limited

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Maheshvari N Patel

Role: CONTACT

09909013236

Sheetal Khandwala

Role: CONTACT

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NB250017-BM_1.0_30June

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Promiseb Topical Cream for Cradle Cap
NCT01214434 COMPLETED PHASE4